Introduction
============

Chronic obstructive pulmonary disease (COPD) is characterized by airflow limitation that is not only progressive but also irreversible.[@b1-copd-10-1599] Inhaled bronchodilators are regarded as foundational pharmacologic agents in the management of patients with COPD, providing not only short-term symptom relief but also reducing the exacerbation frequency and improving the quality of life.[@b1-copd-10-1599] Long-acting muscarinic antagonists (LAMAs) (either alone or in combination with β-agonists) have been found to be effective bronchodilators for the treatment of patients with COPD.[@b1-copd-10-1599] LAMAs may produce typical anticholinergic side effects such as dry mouth, urinary retention, constipation, and nausea.[@b2-copd-10-1599] Inhaled tiotropium administered via soft mist inhaler at moderate and high dosages has been associated with the risk of increased mortality, in particular, cardiovascular mortality.[@b3-copd-10-1599] However, recent trials, such as the Tiotropium Safety and Performance in Respimat (TIOSPIR) study[@b4-copd-10-1599] and other more recent analyses show a mortality risk similar to that of tiotropium in dry powder (HandiHaler^®^) formulation.[@b5-copd-10-1599]--[@b9-copd-10-1599] Glycopyrronium (50 µg), delivered via the Breezhaler^®^ device, is a once-daily (od) LAMA that is indicated for management of patients with COPD. Its efficacy and safety have been demonstrated in various clinical studies.[@b10-copd-10-1599] It is known to be safe and well tolerated while exhibiting sustained 24-hour bronchodilation in patients with moderate-to-severe COPD.[@b11-copd-10-1599] As compared to tiotropium, it has a greater selectivity for the M3 vs M2 receptor, a property that may reduce the risk of cardiovascular adverse events (AEs).[@b12-copd-10-1599] Additionally, it has been shown to exhibit a rapid onset of action as compared to tiotropium, thus allowing for rapid and sustained symptom relief.[@b11-copd-10-1599] To assess the safety of glycopyrronium, we have undertaken an analysis of pooled safety data from clinical trials involving glycopyrronium along with the available data from post-marketing surveillance (PMS) review periods. In this pooled analysis, the safety of glycopyrronium (delivered via the Breezhaler^®^ device) and tiotropium (delivered via the HandiHaler^®^ device) are compared with that of placebo. In the absence of placebo as a comparator, glycopyrronium is also compared with tiotropium.

Methods
=======

All patients provided written informed consent. The comprehensive evaluation of the safety of glycopyrronium in the clinical studies was performed by using two distinct analysis sets that comprise the COPD core safety database (S-db) and the COPD long-term S-db. Studies with the recommended regimen of 50 μg glycopyrronium od, that were randomized double-blinded, placebo- and/or active-controlled, parallel design, with exposure duration of at least 12 weeks in patients with moderate or severe COPD (including following studies: CNVA237A2304 \[GLOW1\],[@b13-copd-10-1599] CNVA237A2303 \[GLOW2\],[@b14-copd-10-1599] CQVA149A2303 \[SHINE\],[@b15-copd-10-1599] CNVA237A2314 \[GLOW5\],[@b16-copd-10-1599] and CNVA237A2309 \[GLOW7\])[@b17-copd-10-1599] were included in the COPD core S-db. Within this database, data were pooled from all studies with similar disease severity, study design, and assessment methods utilized for evaluating AEs, deaths, and events of interest, with results adjusted for the length of exposure and reported as incidence (number of events per 100 patient treatment years \[PTYs, sum of the duration of exposure over patients, in days/365.25 days\]). The COPD long-term S-db included studies with an exposure duration of \>1 year (CQVA149A2304 \[SPARK\],[@b18-copd-10-1599] a double-blinded, active-controlled, parallel design, and an exposure duration of at least 15 months in patients with severe and very severe COPD). The design of six individual studies included in the present analysis is summarized in [Table 1](#t1-copd-10-1599){ref-type="table"}. All the major adverse cardiovascular events and deaths were adjudicated by an external committee using predefined criteria. For the analysis of safety during the PMS review period, patient exposure to glycopyrronium was estimated based on the cumulative worldwide sales volume since its availability (September 28, 2012) for the approved 50 μg dose delivered via the Breezhaler^®^ device, until the cut-off date of March 28, 2014.

Patients
--------

The protocols for all studies were approved by institutional review boards and ethics committees at participating centers, and were conducted in accordance with the Declaration of Helsinki and Good Clinical Practice. All patients provided written informed consent. Overall, the inclusion and exclusion criteria for patients were similar across the studies. The study population in all the trials comprised patients who were at least 40 years of age, had a smoking history of at least 10 pack-years, with post-bronchodilator forced expiratory volume in 1 second (FEV~1~) to forced vital capacity (FVC) ratio of \<0.70 at screening, and diagnosed with moderate-to-severe COPD (Stage II or III according to the GOLD 2005 and 2008 criteria; post-bronchodilator FEV~1~ of ≥30% and \<80% of the predicted normal) with the exception of the SPARK study that enrolled patients with severe-to-very severe COPD (Stage IV according to GOLD 2008; post-bronchodilator FEV~1~ ≤50% predicted).[@b18-copd-10-1599] Additionally, the clinical trial population also comprised patients with a medical history of stable cardiovascular disease.

Safety assessment
-----------------

All analyses were based on the safety population, defined as all patients who received at least one dose of study medication. Common AEs were summarized according to the Medical Dictionary for Regulatory Activities (MedDRA, version 16.0) hierarchy, including primary system organ class and preferred term. Only those events regarded as identified risks (narrow-angle glaucoma, bladder outflow obstruction and urinary retention, and use in patients with severe renal impairment) and potential risks (cerebrovascular events, cardiovascular events including myocardial infarction and cardiac arrhythmias, atrial fibrillation, paradoxical bronchospasm, and medication errors) in the glycopyrronium (Seebri^®^ Breezhaler^®^) risk management plan were searched through Standardized MedDRA Queries (SMQs) and Novartis MedDRA queries (NMQs). SMQs are collections of MedDRA (preferred) terms that relate to a defined medical condition, and allow identification of safety concerns, whereas NMQs are a customized group of search terms that define a medical concept for which there is no SMQ available.

The safety profile of glycopyrronium during the PMS review period was assessed by deriving AEs obtained from individual case study reports from health care professionals, consumers, scientific literature, spontaneous reports, competent authorities, noninterventional studies, and solicited sources such as compassionate use programs.

Furthermore, the safety of glycopyrronium during the PMS review period was also assessed by recording spontaneous voluntary reports of AEs. The EMPIRICA™ Signal System was used to calculate the disproportionality scores of the reported AEs using the Multi-item Gamma Poisson Shrinker (MGPS) algorithm. EMPIRICA™ is an advanced data mining tool used for automated detection and quantification of safety signals, applied to ARGUS™ (a Novartis global S-db that provides a comprehensive AE management system to support the Novartis pharmacovigilance program). The safety data coded by MedDRA (version 16.0) against events marked as "diagnosis" in ARGUS™ (leading events only) were retrieved by EMPIRICA™, after which all the AEs were assigned a statistical score.

Statistical analysis
--------------------

For each event of interest from the clinical data, an estimate of the risk ratio (RR) of incidence density (each respective active treatment vs placebo or active control), together with the 95% confidence interval (CI), was produced through a Poisson regression with treatment and study as class effects in the model.

For the assessment of safety during the PMS review period, the statistical scores (represented as Empirical Bayes Geometric Mean \[EBGM\]) were calculated using the MGPS algorithm. The assignment of EBGM scores was based on the association of glycopyrronium and AEs together (drug-event combination) with a disproportionately high occurrence of reports, as compared to the proportion of reports in the entire ARGUS™ database for glycopyrronium and AEs independently. The lower 90% CI limit of EBGM (denoted as EB05) was used.

EB05 values \<2 were considered as no technical signal and EMPIRICA™ alerted the reviewers if the reporting proportions of AEs were above the threshold value.[@b19-copd-10-1599] EMPIRICA™ calculates the disproportionality scores afresh each time to account for reconciliation of historic safety data. The disproportionality scores presented in this analysis were calculated on July 15, 2014.

Results
=======

Patients and duration of their exposure to treatment
----------------------------------------------------

The analysis of the COPD core S-db included data from 4,178 patients. The length of time for which the patients were exposed to the study drugs is tabulated in [Table 2](#t2-copd-10-1599){ref-type="table"}. The majority of PTYs occurred in patients treated from 3--\>12 months on these studies. The characteristics of the pooled patient population along with other clinical characteristics were comparable across all the treatment groups ([Table 3](#t3-copd-10-1599){ref-type="table"}). There were a few noteworthy differences in the glycopyrronium group vs the other treatment groups: 1) by virtue of the way the studies were designed, the glycopyrronium group exhibited approximately twofold higher patient exposure and enrollment than the tiotropium and placebo groups ([Table 2](#t2-copd-10-1599){ref-type="table"}); 2) more patients were ≥85 years (0.41%, 0.19%, and 0.22%, for glycopyrronium, tiotropium, and placebo groups, respectively) ([Table 3](#t3-copd-10-1599){ref-type="table"}).

Patient exposure during PMS review period
-----------------------------------------

The cumulative worldwide sale of glycopyrronium (at its approved dosage of 50 μg) during the PMS review period is estimated to be approximately 3,332 g of the active pharmaceutical ingredient. Consequently, patient exposure to glycopyrronium (since its first availability and until the cut-off date) is estimated to be approximately 182,562 PTYs.

AEs during clinical studies
---------------------------

The five most common AEs in the glycopyrronium group were COPD worsening, nasopharyngitis, upper respiratory tract infection, cough, and headache ([Table 4](#t4-copd-10-1599){ref-type="table"}). Across all groups, COPD worsening was the most common AE that exhibited the least incidence in the glycopyrronium group. Generally, AEs were well balanced and the rates of occurrence of events for both glycopyrronium and tiotropium treatment arms were similar to that of placebo. The only AEs (among the five most common AEs) observed in \>2% of patients and that numerically increased with glycopyrronium were nasopharyngitis and headache, which occurred with an incidence similar to that of placebo and tiotropium.

Overall, the cardiovascular AE rate was similar for glycopyrronium and placebo although atrial fibrillation was seen more often with glycopyrronium. The most commonly occurring LAMA-specific AEs were dizziness, dry mouth, constipation, nausea, and pyrexia. In general, these events occurred most commonly in the placebo group, with only dry mouth, constipation, and throat irritation modestly increasing with glycopyrronium ([Table 5](#t5-copd-10-1599){ref-type="table"}).

Adjudicated deaths and serious AEs reported during clinical phase
-----------------------------------------------------------------

The incidence of deaths and serious AEs (SAEs) adjusted per PTYs is listed in [Table 6](#t6-copd-10-1599){ref-type="table"}. The occurrence of deaths (exposure adjusted) was comparable across groups. Respiratory cause was the leading reason for deaths among the treatment groups, and was lowest in the glycopyrronium group. Furthermore, the RR for respiratory deaths relative to placebo was slightly lower for glycopyrronium (RR: 1.059 vs placebo; 95% CI -- 0.368, 3.047) than for tiotropium (RR: 1.928 vs placebo; 95% CI -- 0.471, 7.892) ([Table 6](#t6-copd-10-1599){ref-type="table"}). The overall incidence of SAEs (exposure adjusted) in glycopyrronium and tiotropium groups was lower than that in the placebo group. The most commonly occurring SAE was COPD worsening, which was the lowest in the glycopyrronium group.

The incidence of SAEs by preferred term for gastrointestinal, vascular, and renal/urinary disorders was lower than the threshold (\>0.2 events/100 PTYs for glycopyrronium). The overall frequency of occurrence (events/100 PTYs) of SAEs in the various treatment arms was as follows: glycopyrronium (gastrointestinal, 1.317; vascular, 0.790; renal/urinary, 0.439); tiotropium (gastrointestinal, 1.872; vascular, 0; renal/urinary, 0.187); and placebo (gastrointestinal, 2.558; vascular, 0.394; renal/urinary, 0.787).

Cerebrovascular and cardiovascular events during clinical phase
---------------------------------------------------------------

The frequency of occurrence of cerebrovascular and cardiovascular (CCV) events are shown in [Table 7](#t7-copd-10-1599){ref-type="table"} (also refer Supplementary materials, [Tables S1](#SD1-copd-10-1599){ref-type="supplementary-material"}[](#SD2-copd-10-1599){ref-type="supplementary-material"}[](#SD3-copd-10-1599){ref-type="supplementary-material"}--[S4](#SD4-copd-10-1599){ref-type="supplementary-material"}). Glycopyrronium did not result in any increased risk for cardiovascular events in patients in comparison with placebo. Cumulative assessment of the clinical data did not establish any underlying association of cardiovascular events and glycopyrronium. Compared to placebo, both actives, glycopyrronium (RR: 3.805 vs placebo; 95% CI -- 0.875, 16.550) and tiotropium (RR: 1.550, 95% CI -- 0.253, 9.495), exhibited an increase in the exposure-adjusted incidence of atrial fibrillation, although these were not statistically significant ([Tables 7](#t7-copd-10-1599){ref-type="table"}, [S1](#SD1-copd-10-1599){ref-type="supplementary-material"} and [S2](#SD2-copd-10-1599){ref-type="supplementary-material"}). The RR for cerebrovascular events for glycopyrronium (RR: 1.95 vs placebo; 95% CI -- 0.553, 6.870) (95% CI of 0.553, 6.870) was lower than that for tiotropium (RR: 2.62 vs placebo; 95% CI -- 0.626, 10.976) (although at wide CI). The glycopyrronium arm exhibited the least incidence of CCV-related fatal AEs (exposure-adjusted). The incidence of angioedema (exposure-adjusted and defined as Standard MedDRA Query narrow search) for glycopyrronium was similar to that for placebo and tiotropium albeit with numerically lower RR for glycopyrronium: (RR: 1.183 vs placebo; 95% CI -- 0.371, 3.773) compared with tiotropium (RR: 1.474 vs placebo; 95% CI -- 0.394, 5.519) ([Table S4](#SD4-copd-10-1599){ref-type="supplementary-material"}). Overall, the cardiovascular AE rate was similar for glycopyrronium and placebo, although atrial fibrillation events were seen more often with glycopyrronium, although not statistically significant.

Long-term CCV safety (in patients with severe-to-very severe airflow limitation)
--------------------------------------------------------------------------------

The long-term clinical study enrolled patients at risk for exacerbations (defined as patients with severe-to-very severe airflow limitation, Stage III or IV according to GOLD 2008 criteria) and a documented history of at least one exacerbation in the previous 12 months requiring treatment with systemic corticosteroids or antibiotics, or both.

The exposure-adjusted incidence of events related to myocardial infarction, ischemic heart disease, and cardiac arrhythmia was numerically slightly higher for glycopyrronium as compared with tiotropium ([Table 8](#t8-copd-10-1599){ref-type="table"}); however, wide CIs preclude any clinical or statistical significance. The low number of observed cases did not allow meaningful comparison. The RR for the occurrence of cardiac failure was low for glycopyrronium (RR: 0.504 vs tiotropium; 95% CI -- 0.227, 1.122). The incidence of cerebrovascular events (exposure-adjusted) during the long-term period was low compared to that of cardiovascular events, and also similar for tiotropium and glycopyrronium.

Safety during PMS review period
-------------------------------

[Table 9](#t9-copd-10-1599){ref-type="table"} summarizes the incidence of SAEs and non-SAEs during the PMS review phase (ie, from September 28, 2012 to March 28, 2014). By system organ class, the three most commonly occurring events during the PMS phase (in the order of decreasing frequency) were respiratory disorders, followed by gastrointestinal disorders and nervous system disorders. Cough was the most commonly occurring event across all organ system classes during the PMS review period; compared with data from clinical studies, glycopyrronium did not increase the risk of AEs and SAEs in patients during PMS.

The cardiovascular safety profile of glycopyrronium was found to be consistent with the approved label as supported by data from the clinical development program. Furthermore, there was no increase in the severity or incidence of reports related to atrial fibrillation with identification of no new safety concern compared with safety information on the package insert of Seebri^®^ Breezhaler^®^.

Safety analysis during PMS review period using EMPIRICA™
--------------------------------------------------------

Based on the safety data retrieved using EMPIRICA™, EB05 disproportionality scores for all AEs were less than the threshold value (EB05 \<2) except for urinary retention and cardiac arrhythmia, which are well-known side effects of anticholinergic compounds ([Table 10](#t10-copd-10-1599){ref-type="table"}).

Discussion
==========

Analyzing the pooled data from clinical studies and the PMS review period of glycopyrronium offers the first opportunity for a comprehensive assessment of AEs and SAEs related to its use in COPD. The importance of this relates to the possible adverse consequences of LAMA use in this setting. For example, cardiovascular safety concerns had been raised with the use of tiotropium in widespread usage since its launch in January 2004, evident primarily when used via the Respimat^®^ device.[@b3-copd-10-1599],[@b20-copd-10-1599] A comprehensive examination of drug safety often continues beyond the clinical phase leading up to the PMS period, thus providing an opportunity to not only capture the occurrence of expected safety concerns but also those that are infrequent or may be unexpected. The analysis of the data from various clinical studies and the PMS review period showed that glycopyrronium did not increase the risk for any investigated safety points in comparison to placebo, although the incidence of atrial fibrillation was numerically higher with glycopyrronium vs placebo. Anticholinergics are known to be associated with cardiovascular AEs, such as arrhythmias.[@b2-copd-10-1599] The analysis also indicates that safety profile of glycopyrronium was similar to that of tiotropium. COPD worsening was the most common AE and SAE reported in clinical trials, and occurred least frequently with glycopyrronium vs comparators. The long-term safety of glycopyrronium was also very similar to that of tiotropium.

There are some limitations to our analysis. In particular, clinical trials have predefined criteria for inclusion and exclusion of patients that may not always replicate the real-life setting or may not represent clinical characteristics of patients with COPD who receive the approved treatment. In addition, our reliance on incidence rates may have confounded our analysis. The incidence rate of AEs is calculated as the total number of episodes divided by the total patient years. Although this method can account for differences in exposure and appears appropriate for use when the data from patient population is pooled from studies with different exposure duration, there is an implicit assumption that each AE does not increase or decrease in frequency and/or severity over time. This may not be a valid assumption in all the cases. Additionally, the hygroscopic nature of tiotropium makes it challenging to remove the powder from the capsule (marked with manufacturer's logo) to a placebo capsule. In the GLOW2, SHINE (both from COPD core S-db), and SPARK (COPD long-term S-db) studies, tiotropium was dosed open-label, which may have influenced patient expectations. It is possible that in open-label studies, patients receiving the unblinded treatment may over report more favorable outcomes or, under report unfavorable safety signals. Finally, there could also be potential under reporting of AEs available in the ARGUS™ database, which are used as background incidence for calculation.

The comprehensive analysis of safety of glycopyrronium presented here has numerous strengths since it pools data from five randomized clinical trials (from the COPD core S-db) representing more than 4,000 patients with moderate-to-severe COPD. Our analysis also presents long-term safety (\>1 year) of glycopyrronium, specifically in patients with severe-to-very severe COPD (from the COPD long-term S-db), who are at an increased risk of exacerbation.[@b1-copd-10-1599]

Furthermore, the inclusion and exclusion criteria across all studies were similar and so were the clinical characteristics of recruited patients (with the exception of the SPARK study to assess long-term safety). The pooled studies also exhibit an almost identical method of collection of AE reports and allow for the analysis of cardiovascular safety in patients with COPD with different exposure duration. Along with the pooled data from clinical studies, the safety of glycopyrronium was also evaluated during the PMS review period, particularly its cardiac safety. This provides a complete picture of the safety profile of glycopyrronium. Finally, the EMPIRICA™ data mining tool allows using an innovative approach for assessing drug safety for detection of statistics of disproportionate reporting for recognizing emerging trends in spontaneous AE reports for effective pharmacovigilance.

Conclusion
==========

The analysis of pooled data from various clinical studies did not reveal any increase in the overall risk for any of the investigated safety end points. Glycopyrronium exhibited a comparable safety profile to tiotropium and placebo. Furthermore, the safety of glycopyrronium during the PMS review period was consistent with its approved label and did not indicate any clinically important safety findings, indicating a favorable overall benefit-risk balance.

Supplementary materials
=======================

###### 

Number of patients with atrial fibrillation and flutter (adjudicated) adjusted for exposure (COPD core S-db)

                            GLY 50 µg   TIO 18 µg   PBO
  ------------------------- ----------- ----------- ---------
  Overall                                           
   Total population         2,180       1,077       921
   Patients with ≥1 event   44          23          14
   Total patient years      1,138.642   534.234     508.216
   Patients/100 PTYs        3.864       4.305       2.755
  New onset                                         
   Total population         2,124       1,049       900
   Patients with ≥1 event   10          5           1
   Total patient years      1,111.373   519.661     498.042
   Patients/100 PTYs        0.900       0.962       0.201
  Recurrent                                         
   Total population         56          28          21
   Patients with ≥1 event   34          18          13
   Total patient years      27.269      14.574      10.174
   Patients/100 PTYs        124.684     123.511     127.779

**Abbreviations:** COPD, chronic obstructive pulmonary disease; GLY, glycopyrronium; PBO, placebo; PTYs, patient treatment years; S-db, safety database; TIO, tiotropium.

###### 

Number of patients with atrial fibrillation and flutter (adjudicated) adjusted for exposure for long-term safety assessment (COPD long-term S-db)

                            GLY 50 µg   TIO 18 µg
  ------------------------- ----------- -----------
  Overall                               
   Total population         740         737
   Patients with ≥1 event   21          24
   Total patient years      841.645     848.780
   Patients/100 PTYs        2.495       2.828
  New onset                             
   Total population         717         714
   Patients with ≥1 event   6           8
   Total patient years      817.615     825.944
   Patients/100 PTYs        0.734       0.969
  Recurrent                             
   Total population         23          23
   Patients with ≥1 event   15          16
   Total patient years      24.030      22.836
   Patients/100 PTYs        62.422      70.064

**Abbreviations:** COPD, chronic obstructive pulmonary disease; GLY, glycopyrronium; PTYs, patient treatment years; S-db, safety database; TIO, tiotropium.

###### 

Incidence of CCV-related AEs (per 100 patient years) in clinical studies sorted by primary system organ class and preferred term (\>10 events for GLY) (COPD core S-db)

  -----------------------------------------------------------------------------------------
  Primary system organ class, preferred term         GLY 50 µg\   TIO 18 µg\   PBO\
                                                     N=2,180      N=1,077      N=921
  -------------------------------------------------- ------------ ------------ ------------
  Patients with ≥1 AE                                83           31           37

  Number of AEs/100 PTYs                             8.695        7.487        10.822

  Cardiac disorders                                                            

   Total                                             83 (7.289)   27 (5.054)   44 (8.658)

   Atrial fibrillation                               15 (1.317)   4 (0.749)    2 (0.394)

   Angina pectoris                                   10 (0.878)   5 (0.936)    10 (1.968)

   Cardiac failure congestive                        6 (0.527)    1 (0.187)    2 (0.394)

   Ventricular extrasystoles                         6 (0.527)    4 (0.749)    2 (0.394)

   Atrioventricular block first-degree               4 (0.351)    1 (0.187)    2 (0.394)

   Acute coronary syndrome                           3 (0.263)    0            0

   Cardiac failure                                   3 (0.263)    1 (0.187)    0

   Coronary artery disease                           3 (0.263)    0            2 (0.394)

   Myocardial infarction                             3 (0.263)    1 (0.187)    2 (0.394)

   Myocardial ischemia                               3 (0.263)    0            1 (0.197)

   Supraventricular extrasystoles                    3 (0.263)    3 (0.562)    3 (0.590)

   Supraventricular tachycardia                      3 (0.263)    1 (0.187)    4 (0.787)

   Atrial flutter                                    2 (0.176)    0            4 (0.787)

   Bundle branch block left                          2 (0.176)    2 (0.374)    0

   Bundle branch block right                         2 (0.176)    0            0

   Sinus tachycardia                                 2 (0.176)    2 (0.374)    2 (0.394)

   Acute myocardial infarction                       1 (0.088)    0            1 (0.197)

   Arteriosclerosis coronary artery                  1 (0.088)    0            1 (0.197)

   Atrial tachycardia                                1 (0.088)    0            0

   Atrioventricular block                            1 (0.088)    0            0

   Atrioventricular dissociation                     1 (0.088)    0            0

   Cor pulmonale                                     1 (0.088)    0            2 (0.394)

   Cor pulmonale chronic                             1 (0.088)    0            0

   Long QT syndrome                                  1 (0.088)    0            0

   Nodal arrhythmia                                  1 (0.088)    0            0

   Sick sinus syndrome                               1 (0.088)    0            0

   Sinus bradycardia                                 1 (0.088)    0            1 (0.197)

   Tachyarrhythmia                                   1 (0.088)    0            1 (0.197)

   Wandering pacemaker                               1 (0.088)    0            0

   Angina unstable                                   0            0            1 (0.197)

   Arrhythmia                                        0            1 (0.187)    0

   Cardiac failure acute                             0            0            1 (0.197)

   Cardiopulmonary failure                           0            0            1 (0.197)

   Coronary artery insufficiency                     0            1 (0.187)    0

   Right ventricular failure                         0            0            1 (0.197)

   Ventricular tachycardia                           0            0            0

  Nervous system disorders                                                     

   Total                                             13 (1.142)   6 (1.123)    3 (0.590)

   Transient ischemic attack                         5 (0.439)    0            2 (0.394)

   Carotid artery stenosis                           2 (0.176)    0            0

   Carotid artery disease                            1 (0.088)    0            0

   Cerebral arteriosclerosis                         1 (0.088)    0            0

   Cerebral infarction                               1 (0.088)    0            0

   Cerebrovascular accident                          1 (0.088)    2 (0.374)    0

   Thalamus hemorrhage                               1 (0.088)    0            0

   Vertebrobasilar insufficiency                     1 (0.088)    0            1 (0.197)

   Hemorrhagic stroke                                0            1 (0.187)    0

   Ischemic stroke                                   0            2 (0.374)    0

   Spinal hematoma                                   0            1 (0.187)    0

  Respiratory, thoracic, and mediastinal disorders                             

   Total                                             0            0            1 (0.197)

   Pulmonary edema                                   0            0            1 (0.197)

  Injury, poisoning, and procedural complications                              

   Total                                             0            1 (0.187)    0

   Extradural hematoma                               0            1 (0.187)    0

  Investigations                                                               

   Total                                             3 (0.263)    6 (1.123)    7 (1.377)

   Heart rate irregular                              2 (0.176)    0            0

   Electrocardiogram QT prolonged                    1 (0.088)    6 (1.123)    7 (1.377)
  -----------------------------------------------------------------------------------------

**Note:** Values in parentheses are total number of AEs per 100 PTYs.

**Abbreviations:** AEs, adverse events; CCV, cerebrovascular and cardiovascular; COPD, chronic obstructive pulmonary disease; GLY, glycopyrronium; N, patients randomized; PBO, placebo; PTYs, patient treatment years; S-db, safety database; TIO, tiotropium.

###### 

Incidence of angioedema (defined by SMQ)-narrow AE episodes adjusted for exposure by primary system organ class and preferred term with RR and 95% CI (COPD core S-db)

  ----------------------------------------------------------------------------------
                                           GLY 50 µg\     TIO 18 µg\     PBO\
                                           N=2,180        N=1,077        N=921
  ---------------------------------------- -------------- -------------- -----------
  Patients with ≥1 event                   9              4              4

  Episodes/100 PTYs                        0.878          1.123          0.787

  Risk ratio                               1.183          1.474          

  95% CI (lower, upper limit)              0.371, 3.773   0.394, 5.519   

  *P*-value                                0.7762         0.5643         

  Eye disorders                                                          

   Total                                   1 (0.088)      0              1 (0.197)

   Periorbital edema                       1 (0.088)      0              0

   Eye swelling                            0              0              1 (0.197)

  Gastrointestinal disorders                                             

   Total                                   0              2 (0.374)      1 (0.197)

   Lip edema                               0              2 (0.374)      0

   Palatal edema                           0              0              1 (0.197)

  Skin and subcutaneous tissue disorders                                 

   Total                                   9 (0.790)      4 (0.749)      2 (0.394)

   Urticaria                               9 (0.790)      3 (0.562)      2 (0.394)

   Angioedema                              0              1 (0.187)      0
  ----------------------------------------------------------------------------------

**Notes:** Risk ratio values are represented as active vs placebo. Values in parentheses are total number of AEs per 100 PTYs.

**Abbreviations:** AE, adverse event; CI, confidence interval; COPD, chronic obstructive pulmonary disease; GLY, glycopyrronium; N, patients randomized; PBO, placebo; PTYs, patient treatment years; RR, risk ratio; S-db, safety database; SMQ, Standardized MedDRA Query; TIO, tiotropium.
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###### 

Details of studies included in the pooled analysis

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study name                                                          Study design                     Study duration   Patients randomized (N)   Patient population                                         Treatment groups       References
  ------------------------------------------------------------------- -------------------------------- ---------------- ------------------------- ---------------------------------------------------------- ---------------------- ---------------------
  GLOW1 (CNVA237A2304)                                                R, DB, PC, PG                    26 weeks         822                       Moderate-to-severe COPD (Stage II and III, GOLD 2008)      GLY 50 μg od\          [@b13-copd-10-1599]
                                                                                                                                                                                                             PBO od                 

  GLOW2 (CNVA237A2303)                                                R, DB, and OL (TIO), PC, PG      52 weeks         1,066                     Moderate-to-severe COPD (Stage II and III, GOLD 2008)      GLY 50 μg od\          [@b14-copd-10-1599]
                                                                                                                                                                                                             PBO od\                
                                                                                                                                                                                                             OL-TIO 18 μg od        

  GLOW5 (CNVA237A2314)                                                R, DD, PG, BL (TIO)              12 weeks         657                       Moderate-to-severe COPD (Stage II and III, GOLD 2010)      GLY 50 μg od\          [@b16-copd-10-1599]
                                                                                                                                                                                                             Blinded TIO 18 μg od   

  GLOW7 (CNVA237A2309)                                                R, DB, PC, PG                    26 weeks         459                       Moderate-to-severe COPD (Stage II and III, GOLD 2010)      GLY 50 μg od\          [@b17-copd-10-1599]
                                                                                                                                                                                                             PBO od                 

  SHINE[\*](#tfn1-copd-10-1599){ref-type="table-fn"} (CQVA149A2303)   DB and OL (TIO), PG, R, PC, AC   26 weeks         2,144                     Moderate-to-severe COPD (Stage II and III, GOLD 2008)      QVA149 110/50 μg od\   [@b15-copd-10-1599]
                                                                                                                                                                                                             IND 150 μg od\         
                                                                                                                                                                                                             GLY 50 μg od\          
                                                                                                                                                                                                             OL-TIO 18 μg od\       
                                                                                                                                                                                                             PBO od                 

  SPARK[\*](#tfn1-copd-10-1599){ref-type="table-fn"} (CQVA149A2304)   DB and OL (TIO), PG, R           64 weeks         2,224                     Severe-to-very severe COPD (Stage III and IV, GOLD 2008)   QVA149 110/50\         [@b18-copd-10-1599]
                                                                                                                                                                                                             μg od GLY 50 μg od\    
                                                                                                                                                                                                             OL-TIO 18 μg od        
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Note:**

Safety data for IND and QVA149 arms from the SHINE study, and the QVA149 arm from the SPARK study was not included in the current analysis.

**Abbreviations:** AC, active controlled; BL, blinded; COPD, chronic obstructive pulmonary disease; DB, double-blind; DD, double-dummy; GLOW, Glycopyrronium bromide in COPD airWays clinical study; GLY, glycopyrronium; IND, indacaterol; od, once daily; OL, open-label; PBO, placebo; PC, placebo-controlled; PG, parallel-group; R, randomized; TIO, tiotropium.

###### 

Duration of exposure to study drug after randomization (COPD core S-db)

  -------------------------------------------------------------------------------------------------
  Duration of exposure                        GLY 50μg\         TIO 18 μg\        PBO\
                                              N=2,180           N=1,077           N=921
  ------------------------------------------- ----------------- ----------------- -----------------
  Total PTYs                                  1,138.642         534.234           508.216

  PTYs exposure, % of patients (Total PTYs)                                       

   1 day                                      0.41 (0.025)      0.37 (0.011)      0.54 (0.014)

   2 days--\<2 weeks                          1.38 (0.605)      1.11 (0.162)      2.39 (0.408)

   2 weeks--\<1 month                         1.83 (2.502)      1.67 (1.112)      4.13 (2.042)

   1 month--\<3 months                        18.62 (86.439)    30.64 (74.209)    6.51 (9.785)

   3 months--\<6 months                       12.25 (115.269)   10.68 (49.109)    12.49 (51.425)

   6 months--\<12 months                      52.34 (645.478)   41.13 (253.741)   58.09 (297.736)

   ≥12 months                                 13.17 (288.323)   14.39 (155.890)   15.85 (146.806)
  -------------------------------------------------------------------------------------------------

**Abbreviations:** COPD, chronic obstructive pulmonary disease; GLY, glycopyrronium; N, patients randomized; PBO, placebo; PTYs, patient treatment years; S-db, safety database; TIO, tiotropium.

###### 

Characteristics of pooled clinical trial study population (COPD core S-db)

  ------------------------------------------------------------------------------------
  Patient characteristics                  GLY 50 μg\      TIO 18 μg\    PBO\
                                           N=2,180         N=1,077       N=921
  ---------------------------------------- --------------- ------------- -------------
  Age                                                                    

   \<65 years                              1,128 (51.74)   575 (53.39)   455 (49.40)

   65--\<75 years                          792 (36.33)     387 (35.93)   350 (38.00)

   75--\<85 years                          251 (11.51)     113 (10.49)   114 (12.38)

   ≥85 years                               9 (0.41)        2 (0.19)      2 (0.22)

  Sex                                                                    

   Male                                    1,689 (77.48)   776 (72.05)   702 (76.22)

   Female                                  491 (22.52)     301 (27.95)   219 (23.78)

  Race                                                                   

   Caucasian                               1,345 (61.70)   786 (72.98)   557 (60.48)

   Black                                   28 (1.28)       17 (1.58)     15 (1.63)

   Asian                                   758 (34.77)     241 (22.38)   331 (35.94)

   Other                                   49 (2.25)       33 (3.06)     18 (1.95)

  Number of CCV risk factors at baseline                                 

   0                                       217 (9.95)      79 (7.34)     90 (9.77)

   1                                       571 (26.19)     255 (23.68)   236 (25.62)

   2                                       570 (26.15)     286 (26.56)   243 (26.38)

   ≥3                                      822 (37.71)     457 (42.43)   352 (38.22)

  COPD severity                                                          

   Mild                                    2 (0.09)        1 (0.09)      0 (0)

   Moderate                                1,302 (59.72)   661 (61.37)   579 (62.87)

   Severe                                  868 (39.82)     414 (38.44)   338 (36.70)

   Very severe                             8 (0.37)        0 (0)         4 (0.43)

  Steroid use                                                            

   None                                    948 (43.49)     481 (44.66)   427 (46.36)

   ICS                                     1,220 (55.96)   588 (54.60)   491 (53.31)

   OCS                                     3 (0.14)        2 (0.19)      1 (0.11)

   ICS and OCS                             9 (0.41)        6 (0.56)      2 (0.22)

   Baseline diabetes condition             274 (12.57)     141 (13.09)   119 (12.92)
  ------------------------------------------------------------------------------------

**Note:** Values are n (%).

**Abbreviations:** CCV, cerebrovascular and cardiovascular; COPD, chronic obstructive pulmonary disease; GLY, glycopyrronium; ICS, inhaled corticosteroids; N, patients randomized; OCS, oral corticosteroids; PBO, placebo; S-db, safety database; TIO, tiotropium.

###### 

Incidence of most common AEs (per 100 PTYs) in clinical studies sorted by primary system organ class and preferred term (\> 10 events/100 PTYs for GLY) (COPD core S-db)

  ----------------------------------------------------------------------------------------------------
  Primary system organ class, preferred term         GLY 50 μg\        TIO 18 μg\      PBO\
                                                     N=2,180           N=1,077         N=921
  -------------------------------------------------- ----------------- --------------- ---------------
  Patients with ≥ 1 AE, (%)                          1,274 (58.44)     607 (56.36)     586 (63.63)

  Number of AEs/100 PTYs                             342.952           371.373         393.927

  Respiratory, thoracic, and mediastinal disorders                                     

   Total                                             1,221 (107.233)   682 (127.659)   709 (139.508)

   COPD worsening                                    868 (76.231)      510 (95.464)    538 (105.860)

   Cough                                             87 (7.641)        39 (7.300)      39 (7.674)

   Dyspnea                                           53 (4.655)        19 (3.556)      29 (5.706)

   Oropharyngeal pain                                27 (2.371)        14 (2.621)      16 (3.148)

   Sinus congestion                                  16 (1.405)        5 (0.936)       2 (0.394)

   Dysphonia                                         14 (1.230)        7 (1.310)       5 (0.984)

   Nasal congestion                                  12 (1.054)        8 (1.497)       8 (1.574)

   Epistaxis                                         11 (0.966)        5 (0.936)       2 (0.394)

  Infections and infestations                                                          

   Total                                             1,029 (90.371)    546 (102.202)   537 (105.664)

   Nasopharyngitis                                   209 (18.355)      79 (14.788)     93 (18.299)

   Upper RTI                                         170 (14.930)      73 (13.664)     100 (19.677)

   Lower RTI                                         55 (4.830)        34 (6.364)      28 (5.509)

   Bronchitis                                        43 (3.776)        29 (5.428)      24 (4.722)

   Sinusitis                                         42 (3.689)        22 (4.118)      20 (3.935)

   Urinary tract infection                           42 (3.689)        23 (4.305)      13 (2.558)

   Viral upper RTI                                   42 (3.689)        35 (6.551)      38 (7.477)

   Influenza                                         34 (2.986)        18 (3.369)      13 (2.558)

   Pneumonia                                         31 (2.723)        16 (2.995)      22 (4.329)

   Pharyngitis                                       20 (1.756)        17 (3.182)      8 (1.574)

   Rhinitis                                          19 (1.669)        7 (1.310)       4 (0.787)

   Cellulitis                                        12 (1.054)        6 (1.123)       6 (1.181)

   Oral candidiasis                                  12 (1.054)        7 (1.310)       6 (1.181)

   Gastroenteritis                                   11 (0.966)        3 (0.562)       6 (1.181)

   Gastroenteritis viral                             10 (0.878)        4 (0.749)       3 (0.590)

   RTI                                               10 (0.878)        5 (0.936)       3 (0.590)

  Nervous system disorders                                                             

   Total                                             205 (18.004)      82 (15.349)     83 (16.332)

   Headache                                          82 (7.202)        38 (7.113)      33 (6.493)

   Syncope                                           14 (1.230)        0               4 (0.787)

  Cardiac disorders                                                                    

   Total                                             104 (9.134)       34 (6.364)      55 (10.822)

   Atrial fibrillation                               15 (1.317)        4 (0.749)       2 (0.394)

   Angina pectoris                                   10 (0.878)        5 (0.936)       10 (1.968)

  Eye disorders                                                                        

   Total                                             43 (3.776)        23 (4.305)      19 (3.739)

   Cataract                                          10 (0.878)        7 (1.310)       2 (0.394)

  Gastrointestinal disorders                                                           

   Total                                             263 (23.098)      140 (26.206)    138 (27.154)

   Diarrhea                                          29 (2.547)        10 (1.872)      18 (3.542)

   Toothache                                         16 (1.405)        5 (0.936)       4 (0.787)

   Dyspepsia                                         15 (1.317)        6 (1.123)       4 (0.787)

   Abdominal pain                                    13 (1.142)        8 (1.497)       5 (0.984)

   Vomiting                                          13 (1.142)        10 (1.872)      11 (2.164)

   Gastroesophageal reflux disease                   12 (1.054)        9 (1.685)       10 (1.968)
  ----------------------------------------------------------------------------------------------------

**Note:** Values are total number of AEs (AEs/100 PTYs) unless otherwise stated.

**Abbreviations:** AEs, adverse events; COPD, chronic obstructive pulmonary disease; GLY, glycopyrronium; N, patients randomized; PBO, placebo; PTYs, patient treatment years; RTI, respiratory tract infection; S-db, safety database; TIO, tiotropium.

###### 

Incidence of AEs most commonly associated with LAMAs, classified according to primary system organ class and preferred term (COPD core S-db)

  -----------------------------------------------------------------------------------
  Primary system organ class, preferred term   GLY 50 μg\   TIO 18 μg\   PBO\
                                               N=2,180      N=1,077      N=921
  -------------------------------------------- ------------ ------------ ------------
  Total PTYs                                   1,138.642    534.234      508.216

  Nervous system disorders                                               

   Dizziness                                   25 (2.196)   9 (1.685)    13 (2.558)

  Renal and urinary disorders                                            

   Urinary retention                           4 (0.351)    2 (0.374)    0

  Gastrointestinal disorders                                             

   Dry mouth                                   33 (2.898)   14 (2.621)   10 (1.968)

   Constipation                                22 (1.932)   5 (0.936)    9 (1.771)

   Nausea                                      16 (1.405)   11 (2.059)   11 (2.164)

  General disorders                                                      

   Pyrexia                                     35 (3.074)   9 (1.685)    25 (4.919)

  Eye disorders                                                          

   Vision blurred                              5 (0.439)    1 (0.187)    3 (0.590)

   Dry eye                                     3 (0.263)    2 (0.374)    1 (0.197)

  Respiratory disorders                                                  

   Throat irritation                           11 (0.966)   3 (0.562)    4 (0.787)

   Rhinorrhea                                  5 (0.439)    6 (1.123)    10 (1.968)

  Cardiac disorders                                                      

   Tachycardia                                 2 (0.176)    1 (0.187)    4 (0.787)

   Palpitations                                5 (0.439)    2 (0.374)    4 (0.787)
  -----------------------------------------------------------------------------------

**Note:** Values are total number of AEs (AEs/100 PTYs).

**Abbreviations:** AEs, adverse events; COPD, chronic obstructive pulmonary disease; GLY, glycopyrronium; LAMAs, long-acting muscarinic antagonists; N, patients randomized; PBO, placebo; PTYs, patient treatment years; S-db, safety database; TIO, tiotropium.

###### 

Adjudicated deaths, and SAEs (\>0.2 events/100 PTYs for GLY) (COPD core S-db)

  ----------------------------------------------------------------------------------------------
  Primary system organ class, preferred term         GLY 50 μg\     TIO 18 μg\     PBO\
                                                     N=2,180        N=1,077        N=921
  -------------------------------------------------- -------------- -------------- -------------
  Total deaths, n (%)                                11 (0.23)      5 (0.46)       5 (0.54)

  Risk ratio                                         1.059          1.928          

  95% CI (lower, upper limit)                        0.368, 3.047   0.471, 7.892   

  *P*-value                                          0.9160         0.3610         

  Deaths/100 PTYs                                    0.966          0.936          0.984

  Cardiovascular                                     0.263          0.187          0.197

  Respiratory                                        0.351          0.562          0.590

  Cancer                                             0.176          0.187          0

  Unknown                                            0              0              0.197

  Other causes                                       0.176          0              0

  Patients with ≥ 1 SAE                              163            72             94

  Number of SAEs/100 PTYs                            25.205         20.965         35.615

  Respiratory, thoracic, and mediastinal disorders                                 

   Total                                             84 (7.377)     37 (6.926)     61 (12.003)

   COPD worsening                                    54 (4.742)     28 (5.241)     48 (9.445)

   Respiratory failure                               7 (0.615)      2 (0.374)      5 (0.984)

   Dyspnea                                           3 (0.263)      0              2 (0.394)

   Pneumothorax                                      3 (0.263)      2 (0.374)      0

   Acute respiratory failure                         2 (0.176)      2 (0.374)      0

  Infections and infestations                                                      

   Total                                             54 (4.742)     25 (4.680)     35 (6.887)

   Pneumonia                                         19 (1.669)     9 (1.685)      15 (2.951)

   Bronchitis                                        6 (0.527)      2 (0.374)      1 (0.197)

   Upper respiratory tract infection bacterial       5 (0.439)      2 (0.374)      5 (0.984)

   Lower respiratory tract infection                 3 (0.263)      1 (0.187)      3 (0.590)

   Cellulitis                                        3 (0.263)      1 (0.187)      1 (0.197)

  Cardiac disorders                                                                

   Total                                             34 (2.986)     5 (0.936)      16 (3.148)

   Atrial fibrillation                               8 (0.703)      0              0

   Acute coronary syndrome                           3 (0.263)      0              0

   Cardiac failure congestive                        3 (0.263)      1 (0.187)      1 (0.197)

   Myocardial infarction                             3 (0.263)      1 (0.187)      1 (0.197)

   Angina pectoris                                   2 (0.176)      1 (0.187)      3 (0.590)

  Nervous system disorders                                                         

   Total                                             16 (1.405)     8 (1.497)      6 (1.181)

   Syncope                                           6 (0.527)      0              1 (0.197)

   Transient ischemic attack                         4 (0.351)      0              1 (0.197)
  ----------------------------------------------------------------------------------------------

**Notes:** Values are total number of events (events/100 PTYs) unless otherwise stated. Risk ratio values are represented as active vs placebo.

**Abbreviations:** COPD, chronic obstructive pulmonary disease; CI, confidence interval; GLY, glycopyrronium; N, patients randomized; PBO, placebo; PTYs, patient treatment years; SAEs, serious adverse events; S-db, safety database; TIO, tiotropium.

###### 

Incidence of CCV-related AEs and FAEs (defined by SMQ) adjusted for exposure with risk ratio and 95% CI (COPD core S-db)

  ---------------------------------------------------------------------------------------------
  Preferred term                                    GLY 50 μg\      TIO 18 μg\      PBO\
                                                    N=2,180         N=1,077         N=921
  ------------------------------------------------- --------------- --------------- -----------
  Cardiac arrhythmias                                                               

   Number (episodes/100 PTYs)                       51 (4.48)       24 (4.49)       25 (4.92)

   Relative risk                                    0.909           0.770           

   95% CI (lower, upper limit)                      0.562, 1.472    0.431, 1.374    

  *P*-value                                         0.6990          0.3758          

  Myocardial infarction or ischemic heart disease                                   

   Number (episodes/100 PTYs)                       24 (2.11)       7 (1.31)        19 (3.74)

   Relative risk                                    0.585           0.352           

   95% CI (lower, upper limit)                      0.320, 1.071    0.144, 0.863    

   *P*-value                                        0.0824          0.0225          

  Atrial fibrillation                                                               

   Number (episodes/100 PTYs)                       16 (1.41)       3 (0.56)        2 (0.39)

   Relative risk                                    3.805           1.550           

   95% CI (lower, upper limit)                      0.875, 16.550   0.253, 9.495    

   *P*-value                                        0.0748          0.6354          

  Cardiac failure                                                                   

   Number (episodes/100 PTYs)                       11 (0.97)       2 (0.37)        8 (1.57)

   Relative risk                                    0.618           0.264           

   95% CI (lower, upper limit)                      0.246, 1.550    0.052, 1.335    

   *P*-value                                        0.3045          0.1073          

  Cerebrovascular events                                                            

   Number (episodes/100 PTYs)                       13 (1.14)       7 (1.31)        3 (0.59)

   Relative risk                                    1.950           2.620           

   95% CI (lower, upper limit)                      0.553, 6.870    0.626, 10.976   

   *P*-value                                        0.2986          0.1875          

   Patients with ≥ 1                                1               1               1

   CCV-related FAEs                                                                 

   Number of CCV-related FAEs/100 PTYs              0.088           0.187           0.197

   Cardiopulmonary failure                          0               0               1 (0.197)

   Thalamus hemorrhage                              1 (0.088)       0               0

   Myocardial infarction                            0               1 (0.187)       0
  ---------------------------------------------------------------------------------------------

**Notes:** CCV condition determined based on the following predefined search criteria: Cerebrovascular disorders (SMQ) (narrow); Cardiac arrhythmia terms (including bradyarrhythmias and tachyarrhythmias) (SMQ) (broad); Myocardial infarction (SMQ) (narrow); Other ischemic heart disease (SMQ) (narrow); Cardiac failure (SMQ) (narrow); Sudden death (PT); Sudden cardiac death (PT). Risk ratio values are represented as active vs placebo; Episodes/100 PTYs =100× (n/total PTYs). Values are number of AEs/100 PTYs (n/total PTYs) ×100.

**Abbreviations:** AEs, adverse events; CCV, cerebrovascular and cardiovascular; CI, confidence interval; COPD, chronic obstructive pulmonary disease; FAEs, fatal AEs; GLY, glycopyrronium; N, patients randomized; PBO, placebo; PTYs, patient treatment years; RR, risk ratio; S-db, safety database; SMQ, Standardized MedDRA Query; TIO, tiotropium.

###### 

Incidence of cerebrovascular and cardiovascular AEs (defined by SMQ) during long-term (≥ 1 year) period and adjusted for exposure with risk ratio and 95% CI (COPD long-term S-db)

  -----------------------------------------------------------------------------
  Preferred term                                    GLY 50 μg\     TIO 18 μg\
                                                    N=740          N=737
  ------------------------------------------------- -------------- ------------
  Cardiac arrhythmias                                              

   Number (episodes/100 PTYs)                       29 (3.45)      16 (1.89)

   Relative risk                                    1.828          

   95% CI (lower, upper limit)                      0.993, 3.365   

   *P*-value                                        0.0528         

  Myocardial infarction or ischemic heart disease                  

   Number (episodes/100 PTYs)                       26 (3.09)      19 (2.24)

   Relative risk                                    1.380          

   95% CI (lower, upper limit)                      0.764, 2.493   

   *P*-value                                        0.2859         

  Atrial fibrillation                                              

   Number (episodes/100 PTYs)                       14 (1.66)      9 (1.06)

   Relative risk                                    1.569          

   95% CI (lower, upper limit)                      0.679, 3.624   

   *P*-value                                        0.2919         

  Cardiac failure                                                  

   Number (episodes/100 PTYs)                       9 (1.07)       18 (2.12)

   Relative risk                                    0.504          

   95% CI (lower, upper limit)                      0.227, 1.122   

   *P*-value                                        0.0935         

  Cerebrovascular events                                           

   Number (episodes/100 PTYs)                       9 (1.07)       10 (1.18)

   Relative risk                                    0.908          

   95% CI (lower, upper limit)                      0.369, 2.234   

   *P*-value                                        0.8329         
  -----------------------------------------------------------------------------

**Notes:** CCV condition determined based on the following predefined SMQ search criteria: Angioedema (narrow scope); Cerebrovascular disorders (narrow); Cardiac arrhythmia (including bradyarrhythmias and tachyarrhythmias) (broad); Myocardial infarction (narrow); Other ischemic heart disease (narrow). Risk ratio values are represented as glycopyrronium vs tiotropium.

**Abbreviations:** AEs, adverse events; CCV, cerebrovascular and cardiovascular; CI, confidence interval; COPD, chronic obstructive pulmonary disease; GLY, glycopyrronium; N, patients randomized; PTYs, patient treatment years; RR, risk ratio; S-db, safety database; SMQ, standardized MedDRA Query; TIO, tiotropium.

###### 

Summary of serious and nonserious adverse reactions during PMs sorted by primary system organ class and preferred term

  Primary system organ class, preferred term         Total reports[a](#tfn16-copd-10-1599){ref-type="table-fn"}   Reporting frequency[b](#tfn17-copd-10-1599){ref-type="table-fn"}
  -------------------------------------------------- ------------------------------------------------------------ ------------------------------------------------------------------
  Respiratory, thoracic, and mediastinal disorders                                                                
   Total                                             263                                                          0.144
   Cough                                             59                                                           0.032
   Dyspnea                                           55                                                           0.030
   Epistaxis                                         25                                                           0.014
   Dysphonia                                         17                                                           0.009
   Throat irritation                                 17                                                           0.009
   Oropharyngeal pain                                16                                                           0.009
  Gastrointestinal disorders                                                                                      
   Total                                             223                                                          0.122
   Dry mouth                                         38                                                           0.021
   Diarrhea                                          32                                                           0.018
   Nausea                                            24                                                           0.013
   Upper abdominal pain                              16                                                           0.009
   Constipation                                      12                                                           0.007
  Nervous system disorders                                                                                        
   Total                                             106                                                          0.058
   Headache                                          43                                                           0.024
   Dizziness                                         13                                                           0.007
   Dysgeusia                                         12                                                           0.007
  Skin and subcutaneous tissue disorders                                                                          
   Total                                             81                                                           0.044
   Rash                                              22                                                           0.012
   Pruritus                                          11                                                           0.006
  Cardiac disorders                                                                                               
   Total                                             74                                                           0.041
   Palpitations                                      23                                                           0.013
   Tachycardia                                       13                                                           0.007
  Renal and urinary disorders                                                                                     
   Total                                             72                                                           0.039
   Urinary retention                                 18                                                           0.010
   Dysuria                                           16                                                           0.009
   Pollakiuria                                       11                                                           0.006
  Musculoskeletal disorders                                                                                       
   Total                                             71                                                           0.039
   Myalgia                                           17                                                           0.009
   Pain in extremity                                 14                                                           0.008
  Eye disorders                                                                                                   
   Total                                             66                                                           0.036
   Visual impairment                                 12                                                           0.007
  Psychiatric disorders                                                                                           
   Total                                             44                                                           0.024
  Insomnia                                           16                                                           0.009

**Notes:**

Includes serious and nonserious adverse reactions.

Incidence is reported only for events that occurred with a frequency of 0.007/100 PTYs.

**Abbreviations:** PMS, post-marketing surveillance; PTYs, patient treatment years.

###### 

Statistical scores for AEs of clinical interest during the PMS phase

  Preferred term (leading event)                                                       EB05 disproportionality scores
  ------------------------------------------------------------------------------------ --------------------------------
  Angioedema(SMQ-narrow)                                                               0.787
  Angioedema(SMQ-broad)                                                                0.739
  Atrial fibrillation                                                                  1.768
  Cardiac arrhythmia (nonspecific SMQ-broad)                                           0.777
  Cardiac arrhythmia terms[\*](#tfn19-copd-10-1599){ref-type="table-fn"} (SMQ-broad)   1.398
  Cardiac failure (SMQ-narrow)                                                         0.598
  Cardiac failure (SMQ-broad)                                                          0.417
  Glaucoma (SMQ-narrow)                                                                0.99
  Glaucoma(SMQ-broad)                                                                  0.443
  Myocardial infarction (SMQ-narrow)                                                   0.223
  Myocardial infarction (SMQ-broad)                                                    0.277
  Urinary retention                                                                    5.699
  Urinary tract disorder                                                               0.264

**Notes:**

Including bradyarrhythmias and tachyarrhythmias. EB05 disproportionality scores represent the lower 90% CI limit of empirical Bayes Geometric Mean.

**Abbreviations:** AEs, adverse events; PMs, post-marketing surveillance; SMQ, Standardized MedDRA Query.
